Keywords
Parkinson; 6-OHDA; Ramelteon; Neuroinflammation; NF-?B pathway
Abstract
Parkinson’s Disease (PD) is a serious neurodegenerative disease, especially in the elderly population, with a very high incidence and no effective clinical treatment. Ramelteon is a melatonin receptor agonist that can be used to treat sleep-resistant insomnia, and it also has a definite effect on chronic insomnia and short-term insomnia, and is the first non-addictive insomnia treatment drug that is not listed as a special control. Ramelteon has been shown to alleviate inflammation and oxidative stress by activating the Nrf2 signaling pathway, thereby preventing traumatic brain injury. Ramelteon has also been shown to delay cell senescence in the Parkinson’s model of human SH-SY5Y neuronal cells, however, no studies have shown whether Ramelteon can alleviate Parkinson’s by inhibiting neuroinflammation. To this end, this study investigated whether Ramelteon can achieve a neuroprotective effect on 6-OHDA-treated human SH-SY5Y neuronal cells and Parkinson’s mouse models through the NF-κB pathway. In this study, we found that Ramelteon could potently inhibit ROS release from 6-OHDA-treated SH-SY5Y neuronal cells, improve dyskinesia in Parkinson’s mouse models, and effectively inhibit neuroinflammation via the NF-κB pathway. In conclusion, Ramelteon can inhibit neuroinflammation through the NF-κB pathway, thereby achieving neuroprotective effects on Parkinson’s mouse models.
Citation
Wang CC, Xing HN, Liu XM, Yu F, Qi ZQ et.al., (2024) Neuro protective Effects of Ramelteon on Inflammation via the NF-κB Pathway in a Mouse Model of Parkinson’s Disease. SM J Pharmacol Therapeut 7: 8.